ArticleCell transplantation2018
Bone Marrow CD133
Article in Cell transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Potential therapeutic applications of stem cells in animal models of ocular affections.Inflammation and regeneration · 2025Review
- Optic Nerve Regeneration in Diabetic Retinopathy: Potentials and Challenges Ahead.International journal of molecular sciences · 2023Review
- Experiment-Based Interventions to Diabetic Retinopathy: Present and Advances.International journal of molecular sciences · 2022Review
- A Microfluidic Eye Facsimile System to Examine the Migration of Stem-like Cells.Micromachines · 2022Article
- Effects of the Surface Charge of Graphene Oxide Derivatives on Ocular Compatibility.Nanomaterials (Basel, Switzerland) · 2022Article
- Human Umbilical Cord Blood-Derived CD133Frontiers in cell and developmental biology · 2022Article
- Glucocorticoids Promote Extracellular Matrix Component Remodeling by Activating YAP in Human Retinal Capillary Endothelial Cells.Frontiers in cell and developmental biology · 2021Article
- The effect of spleen tyrosine kinase inhibitor R406 on diabetic retinopathy in experimental diabetic rats.International ophthalmology · 2020Article
- Genotypic variability in radial resistance to water flow in olive roots and its response to temperature variations.Tree physiology · 2020Article
- Mechanisms behind Retinal Ganglion Cell Loss in Diabetes and Therapeutic Approach.International journal of molecular sciences · 2020Review
- Recent Developments in Diabetic Retinal Neurodegeneration: A Literature Review.Journal of diabetes research · 2020Review
- Effects of intravitreal injection of human CD34Experimental eye research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR), one of the leading causes of vision loss worldwide, is characterized by neurovascular disorders. Emerging evidence has demonstrated retinal neurodegeneration in the early pathogenesis of DR, and no treatment has been developed to prevent the early neurodegenerative changes that precede detectable microvascular disorders. Bone marrow CD133
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.